InvestorsHub Logo
Post# of 253175
Next 10
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

Re: willyw post# 222221

Tuesday, 11/13/2018 12:13:22 PM

Tuesday, November 13, 2018 12:13:22 PM

Post# of 253175
ABBV/ENTA—The GT3-cirrhotic cohort is still in progress, according to today’s PR (in your post).

If it turns out that 8 weeks of Mavyret suffices for cirrhotic patients of any genotype, it will be quite a coup for ABBV/ENTA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.